2-ethyl-4-methylimidazole

Toxicity to reproduction

Administrative data

Endpoint:

one-generation reproductive toxicity

Remarks:

based on generations indicated in Effect levels (migrated information)

Type of information:

experimental study

Adequacy of study:

key study

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

guideline study

Cross-reference

Reason / purpose for cross-reference:

reference to same study

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

2012

Report date:

2012

Materials and methods

Test guideline

Test guideline 1

Qualifier:

according to guideline

Guideline:

OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)

Test guideline 2

Qualifier:

according to guideline

Guideline:

other: EPA OPPTS 870.3650 (Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test)

GLP compliance:

yes

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

2-ethyl-4-methylimidazole

EC Number:

213-234-5

EC Name:

2-ethyl-4-methylimidazole

Cas Number:

931-36-2

Molecular formula:

C6H10N2

IUPAC Name:

2-ethyl-4-methyl-1H-imidazole

Details on test material:

- Name of test material (as cited in study report): 2-ethyl-4-methylimidazole
- Molecular formula: C6H10N2
- Molecular weight: 110.157
- Description: Yellowish solid
- Purity: 98.0% (1H-NMR),
- Storage: At room temperature in the dark
- Stability under storage conditions: Stable
- Expiry date: 15 July 2012

Test animals

Species:

rat

Strain:

Wistar

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Source: Charles River Deutschland, Sulzfeld, Germany.
- Age at study initiation: Approximately 11 weeks
- Weight at study initiation: Males: 287-315g, Females: 184-217g
- Housing: Pre-mating: Animals were housed in groups of 5 animals/sex/cage in Macrolon plastic cages (MIV type, height 18 cm). Mating: Females were caged together with males on a one-to-one-basis in Macrolon plastic cages (MIII type, height 18 cm). Post-mating: Males were housed in their home cage (Macrolon plastic cages, MIV type, height 18 cm) with a maximum of 5 animals/cage. Females were individually housed in Macrolon plastic cages (MIII type, height 18 cm). Lactation: Pups were kept with the dam until termination in Macrolon plastic cages (MIII type, height 18 cm). During locomotor activity monitoring of the dams the pups were kept warm in their home cage using bottles filled with warm water. In order to avoid hypothermia of pups, pups were not left without their dam or a bottle filled with warm water for longer than 30-40 minutes. General: Sterilized sawdust as bedding material (Litalabo, S.P.P.S., Argenteuil, France) and paper as cage-enrichment/nesting material (Enviro-dri, Wm. Lillico & Son (Wonham Mill Ltd), Surrey, United Kingdom) were supplied. Certificates of analysis were examined and then retained in the WIL Research B.V. archives. During locomotor activity monitoring, animals were housed individually in a Hi-temp polycarbonate cage (Ancare corp., USA; dimensions: 48.3 x 26.7 x 20.3 cm) without cage-enrichment or bedding material.
- Diet: Free access to pelleted rodent diet (SM R/M-Z from SSNIFF® Spezialdiäten GmbH, Soest, Germany). Results of analyses for nutrients and contaminants were examined and archived.
- Water: Free access to tap-water. Certificates of analysis (performed quarterly)
were examined and archived.
- Acclimation period: At least 5 days prior to start of treatment

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 18-24
- Humidity (%): 40-70
- Air changes (per hr): approx. 15
- Photoperiod (hrs dark / hrs light): 12/12

Administration / exposure

Route of administration:

oral: gavage

Vehicle:

water

Details on exposure:

- Amount of vehicle: 5 mL/kg body weight

Details on mating procedure:

- Mating procedures: Following a minimum of 14 days of exposure for the males and females, one female was cohabitated with one male of the same treatment group, avoiding sibling mating. Detection of mating was confirmed by evidence of sperm in the vaginal lavage or by the appearance of an intravaginal copulatory plug. This day was designated Day 0 post-coitum. Once mating occurred, the males and females were separated. After 14 days of mating, female nos. 42, 43 and 48 from the control group (Group 1) did not show evidence of mating. Therefore, they were separated from their males and cohabited with proven males (nos. 7, 9 and 10) from the same group on 11 May 2012. Until 14 May 2012, nine Group 1 females in total showed evidence of mating. As this was the required minimum number of mated females, re-mating was suspended.

Analytical verification of doses or concentrations:

yes

Details on analytical verification of doses or concentrations:

- Chemical analysis of dose preparations: Analyses were conducted on a single occasion during the treatment phase (01 May 2012), according to a validated method (Project 499238; BASF Project 05Y0379/05X022). Samples of formulations were analyzed for homogeneity (highest and lowest concentration) and accuracy of preparation (all concentrations). Stability in vehicle over 6 hours at room temperature under normal laboratory light conditions was also determined (highest and lowest concentration). The accuracy of preparation was considered acceptable if the mean measured concentrations were 90-110% of the target concentration. Homogeneity was demonstrated if the coefficient of variation was ≤ 10%. Formulations were considered stable if the relative difference before and after storage was maximally 10%.
- Analysis of dose preparations: The concentrations analysed in the formulations of Group 2, Group 3 and Group 4 were in agreement with target concentrations (i.e. mean accuracies between 90% and 110%). No test substance was detected in the Group 1 formulation. The formulations of Group 2 and Group 4 were homogeneous (i.e. coefficient of variation ≤ 10%). Formulations at the entire range were stable when stored at room temperature under normal laboratory light conditions for at least 6 hours.

Duration of treatment / exposure:

Males were exposed for 29 days, i.e. 2 weeks prior to mating, during mating, and up to the day prior to scheduled necropsy. Females were exposed for 43-56 days, i.e. during 2 weeks prior to mating, during mating, during post-coitum, and during at least 4 days of lactation (up to the day prior to scheduled necropsy). Female nos. 43, 45 (Group 1), 51, 53, 56, 58 (Group 2) were not dosed during littering.

Frequency of treatment:

Once daily for 7 days per week, approximately the same time each day with a maximum of 6 hours difference between the earliest and latest dose. Animals were dosed up to the day prior to scheduled necropsy.

Doses / concentrations

Remarks:

Doses / Concentrations:
15, 50, 150 mg/kg bw
Basis:
actual ingested

No. of animals per sex per dose:

10

Control animals:

yes, concurrent vehicle

Details on study design:

- Dose selection rationale: In a previous dose range finding study (Project 499236; BASF Project 01R0379/05X016), groups of 4 male and 4 female Crl:WI(Han) rats received 2-Ethyl-4-methylimidazole by oral gavage for a period of 14 days at the dose levels of 0, 50, or 150 mg/kg bw/day. Test substance related adverse effects were noted at 150 mg/kg bw/day only. Changes were transient and/or slight and consisted of transient clinical signs (rales, hunched posture, piloerection, chromodacryorrhoea, and/or ptosis; one male and one female), and initially slightly lower body weight gains (males) and food consumption (absolute and relative to body weight; both sexes). Clinical laboratory investigations revealed a higher count of white blood cells and platelets (males), and higher cholesterol levels (both sexes) at 150 mg/kg bw/day. There were no adverse effects on either macroscopy or organ weights. No adverse findings were noted at 50 mg/kg bw/day. Based on these results, dose levels of 0, 15, 50, or 150 mg/kg bw/day were selected for the present study, taking into account the longer administration period and inclusion of pregnant animals.
- Method of formulation: The test substance was melted at approximately 60-65°C, divided in suitable portions and stored at room temperature in the dark until preparation of the formulation. Formulations (w/w) were prepared daily within 6 hours prior to dosing. The vehicle was added to the pre-weighed test substance and the formulations were heated (at approximately 60-65°C) and stirred continuously (magnetic stirrer) for approximately 15 minutes to achieve homogeneity at a visually acceptable level. Subsequently, dose preparations were allowed to cool down to a maximum of 40°C before dosing. No adjustment was made for specific gravity/density of the test substance, vehicle, and/or formulation. No adjustment was made for the purity of the test substance.
- Treatment: By oral gavage, using a plastic feeding tube. Formulations were placed on a magnetic stirrer during dosing. Due to the relatively high pH-values of the dose preparations for Groups 2-4, preventative measures were taken to avoid possible local esophageal and/or gastrointestinal effects: Wiping of the flexible catheter prior to dosing of each animal and additional rinsing of the flexible catheter with approximately 0.5-0.6 mL water (Elix, Millipore S.A.S., Molsheim, France) after dosing each animal with the test formulations.
- Parturition: The females were allowed to litter normally. Day 1 of lactation was defined as the day when a litter was found completed (i.e. membranes and placentas cleaned up, nest build up and/or feeding of pups started). Females that were littering were left undisturbed.

Examinations

Parental animals: Observations and examinations:

- Mortality / Viability: At least twice daily.
- Clinical signs: At least once daily from start of treatment onwards, detailed clinical observations were made for all animals. Once prior to start of treatment and at weekly intervals during the treatment period this was also performed outside the home cage in a standard arena. In the period from treatment Days 1-12 (i.e. 16-27 April 2012), clinical observations were conducted at least between 1 and 2 hours after dosing (based on results of the dose range finding study, Project 499236; BASF Project 01R0379/05X016). However, since from treatment Day 12 onwards animals from Groups 3 and 4 showed salivation immediately after dosing, the time point for detailed observations for clinical signs (incl. arena observations) was changed to immediately after dosing from treatment Day 13 (28 April 2012) onwards. The time of onset, grade and duration of any observed sign were recorded. Signs were graded for severity and the maximum grade was predefined at 3 or 4. Grades were coded as slight (grade 1), moderate (grade 2), severe (grade 3) and very severe (grade 4). For certain signs, only its presence (grade 1) or absence (grade 0) was scored.
- Functional Observations: The following tests were performed on the selected 5 animals/sex/group: hearing ability, pupillary reflex, static righting reflex, grip strength, locomotor activity (recording period: 1-hour under normal laboratory light conditions, using a computerized monitoring system, Kinder Scientific LLC, Poway, USA). Total movements and ambulations are reported. Ambulations represent movements characterized by a relocation of the entire body position like walking, whereas total movements represent all movements made by the animals, including ambulations but also smaller or more fine movements like grooming, weaving or movements of the head. During motor activity monitoring, all animals were caged individually (pups were housed in their home cages and kept warm using bottles filled with warm water). The selected males were tested during Week 4 of treatment and the selected females were tested towards the end of the scheduled lactation period (all before blood sampling). These tests were performed as soon as possible after observation for clinical signs (incl. arena observation, if applicable), and before blood sampling.
- Body weights: Males and females were weighed on the first day of exposure and weekly thereafter. Mated females were weighed on Days 0, 4, 7, 11, 14, 17 and 20 post-coitum and during lactation on Days 1 and 4.
- Food consumption: Weekly, except for males and females which were housed together for mating and for females without evidence of mating. Food consumption of mated females was measured on Days 0, 4, 7, 11, 14, 17 and 20 postcoitum and on Days 1 and 4 of lactation.
- Water consumption: Subjective appraisal was maintained during the study, but no quantitative investigation was introduced as no treatment related effect was suspected.
- General reproduction data: Male number paired with, mating date, confirmation of pregnancy, and delivery day were recorded. Pregnant females were examined to detect signs of difficult or prolonged parturition, and cage debris of pregnant females was examined to detect signs of abortion or premature birth. Any deficiencies in maternal care (such as inadequate construction or cleaning of the nest, pups left scattered and cold, physical abuse of pups or apparently inadequate lactation or feeding) were examined.
- Clinical laboratory investigations: Blood samples were collected from the selected 5 animals/sex/group under anaesthesia using isoflurane (Abbott B.V., Hoofddorp, The Netherlands) between 7.00 and 10.30 a.m. The animals were deprived of food overnight (with a maximum of 24 hours) before blood sampling, but water was provided. Blood samples were drawn from the retro-orbital sinus and collected into tubes (Greiner Bio-One GmbH, Kremsmünster, Austria) prepared with EDTA for haematological parameters (0.5 mL), with citrate for clotting tests (0.45 mL) and Li-heparin treated tubes for clinical biochemistry parameters (0.5 mL). An additional blood sample (0.25 mL) was collected into untreated tubes for determination of bile acids. Furthermore, from the selected 5 animals/sex/group an additional blood sample (0.5 mL) was collected into serum tubes for possible future measurement of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). Under these storage conditions, T3 and T4 was stable for 2 months. Since histopathological examination revealed no treatment related changes in the thyroid glands, no thyroid hormone measurements were required. The blood samples were discarded at finalization of the study report.
- Haematology: The following haematology parameters were determined in blood prepared with EDTA as an anticoagulant, using the ADVIA® 120 Hematology System (Siemens Healthcare Diagnostics B.V., Breda, The Netherlands): White blood cells, Differential leucocyte count: Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, Red blood cells, Reticulocytes, Red blood cell distribution width, Haemoglobin, Haematocrit, Mean corpuscular volume, Mean corpuscular haemoglobin, Mean corpuscular haemoglobin concentration, Platelets. The following clotting parameters were determined in plasma prepared with citrate as anti-coagulant, using the STA Compact® (Diagnostica Stago S.A.S., Asnières, France): Prothrombin Time, Activated Partial Thromboplastin Time.
- Clinical biochemistry: The following clinical biochemistry parameters were determined using the AU400® Chemistry System (Beckman Coulter Nederland B.V., Woerden, The Netherlands). All parameters were determined in plasma, except for bile acids which were determined in serum: Alanine aminotransferase, Aspartate aminotransferase, Alkaline Phosphatase, Total protein, Albumin, Total Bilirubin, Bile acids, Urea, Creatinine, Glucose, Cholesterol, Sodium, Potassium, Chloride, Calcium, Inorganic Phosphate.

Litter observations:

- Mortality / Viability: The numbers of live and dead pups on Day 1 of lactation and daily thereafter were determined. If possible, defects or cause of death were evaluated.
- Clinical signs: At least once daily, detailed clinical observations were made for all animals.
- Body weights: Live pups were weighed on Days 1 and 4 of lactation.
- Sex: Sex was determined for all pups on Days 1 and 4 of lactation.

Postmortem examinations (parental animals):

- Necropsy: All males, the selected females/group were deprived of food overnight (with a maximum of 24 hours) prior to planned necropsy, but water was provided. Non-selected females were not deprived of food. Animals surviving to scheduled necropsy were deeply anaesthetized using isoflurane (Abbott B.V., Hoofddorp, The Netherlands) and subsequently exsanguinated. Necropsy was conducted on the following days: Females which delivered: Lactation Days 5-7, Females which failed to deliver: Post-coitum Day 28 (females with evidence of mating) or 21 days after the last day of the mating period (female without evidence of mating), Males: Following completion of the mating period (a minimum of 28 days of dose administration). All animals were subjected to macroscopic examination of the cranial, thoracic and abdominal tissues and organs, with special attention being paid to the reproductive organs. Descriptions of all macroscopic abnormalities were recorded. The numbers of former implantation sites and corpora lutea were recorded for all paired females (for females which failed to deliver: In case no macroscopically visible implantation sites were present, nongravid uteri were stained using the Salewski technique in order to detect any former implantation sites). Samples of the following tissues and organs were collected from all animals and fixed in 10% buffered formalin (neutral phosphate buffered 4% formaldehyde solution, Klinipath, Duiven, The Netherlands): Adrenal glands, (Aorta), Brain - cerebellum, mid-brain, cortex, Caecum, Cervix, Clitoral gland, Colon, Coagulation gland, Duodenum, Epididymides, Eyes (with optic nerve (if detectable) and Harderian gland), (Male and Female mammary gland area), Femur including joint, Heart, Ileum, Jejunum, Kidneys, (Lacrimal gland, exorbital), (Larynx), Liver, Lung, infused with formalin, Lymph nodes - mandibular, mesenteric, (Nasopharynx), (Esophagus), Ovaries, (Pancreas), Peyer's patches [jejunum, ileum] if detectable, Pituitary gland, Preputial gland, Prostate gland, Rectum, (Salivary glands - mandibular, sublingual), Sciatic nerve, Seminal vesicles, Skeletal muscle, (Skin), Spinal cord -cervical, midthoracic, lumbar, Spleen, Sternum with bone marrow, Stomach (forestomach and glandular stomach), Testes, Thymus, Thyroid including parathyroid if detectable, (Tongue), Trachea, Urinary bladder, Uterus, Vagina, All gross lesions. The epididymides, eyes and testes were fixed in modified Davidson's solution and Milli-Ro water and transferred to formalin after fixation for at least 24 hours. Tissues/organs mentioned in parentheses were not examined by the pathologist, since no signs of toxicity were noted at macroscopic examination.
- Organ weights: The following organ weights and terminal body weight were recorded from the following animals on the scheduled day of necropsy: Adrenal glands, Brain, Epididymides, Heart, Kidneys, Liver, Ovaries, Spleen, Testes, Thymus, Uterus (including cervix), Prostate (weighed when fixed for at least 24 hours), Seminal vesicles including coagulating glands (weighed when fixed for at least 24 hours), Thyroid including parathyroid (weighed when fixed for at least 24 hours). All remaining males: Epididymides, Testes.
- Histotechnology: All organ and tissue samples, as defined under Histopathology (following section), were processed, embedded and cut at a thickness of 2-4 micrometers and stained with haematoxylin and eosin (Klinipath, Duiven, The Netherlands). Of all males of the control and high dose group and all males suspected to be infertile, additional slides of the testes were prepared to examine staging of spermatogenesis. The testes were processed, sectioned at 3-4 micrometers, and stained with PAS/haematoxylin (Klinipath, Duiven, The Netherlands).
- Histopathology: The following slides were examined by a pathologist: (1) The preserved organs and tissues of the selected 5 animals/sex of Groups 1 and 4. (2) The additional slides of the testes of all males of Groups 1 and 4 and all males suspected to be infertile or which died before mating to examine staging of spermatogenesis. (3) All gross lesions of all animals (all dose groups). (4) The spleen and kidneys of all selected 5 females of Groups 2 and 3, based on (possible) treatment-related changes in these organs in Group 4. (5) The reproductive organs (cervix, clitoral gland, coagulation gland, epididymides, ovaries, preputial gland, prostate gland, seminal vesicles, testes, uterus, and vagina) from all animals of Groups 1 and 4 and from all males that failed to sire and all females that failed to deliver healthy pups.

Postmortem examinations (offspring):

Pups surviving to planned termination were killed by decapitation on Days 5-7 of lactation. All pups were sexed and descriptions of all external abnormalities were recorded. The stomach was examined for the presence of milk. If possible, defects or cause of death were evaluated.

Statistics:

The following statistical methods were used to analyze the data:
- If the variables could be assumed to follow a normal distribution, the Dunnett-test (many-to-one t-test) based on a pooled variance estimate was applied for the comparison of the treated groups and the control groups for each sex.
- The Steel-test (many-to-one rank test) was applied if the data could not be assumed to follow a normal distribution.
- The Fisher Exact-test was applied to frequency data.
- Motor activity data was subjected to the Kruskal-Wallis nonparametric ANOVA test to determine intergroup differences followed by the Wilcoxon test to compare the treated groups to the control group.
All tests were two-sided and in all cases p < 0.05 was accepted as the lowest level of significance. Group means were calculated for continuous data and medians were calculated for discrete data (scores) in the summary tables. Test statistics were calculated on the basis of exact values for means and pooled variances. Individual values, means and standard deviations may have been rounded off before printing. Therefore, two groups may display the same printed means for a given parameter, yet display different test statistics values.

Reproductive indices:

For each group, the following calculations were performed:
- Mating index (%) = (Number of females mated / Number of females paired) x 100
- Fertility index (%) = (Number of pregnant females / Number of females paired) x 100
- Conception index (%) = (Number of pregnant females / Number of females mated) x 100
- Gestation index (%) = (Number of females bearing live pups / Number of pregnant females) x 100
- Duration of gestation = Number of days between confirmation of mating and the beginning
of parturition

Offspring viability indices:

For each group, the following calculations were performed:
- Percentage live males at First Litter Check = (Number of live male pups at First Litter Check / Number of live pups at First Litter Check) x 100
- Percentage live females at First Litter Check = (Number of live female pups at First Litter Check / Number of live pups at First Litter Check) x 100
- Percentage of postnatal loss Days 0-4 of lactation = (Number of dead pups on Day 4 of lactation / Number of live pups at First Litter Check) x 100
- Viability index = (Number of live pups on Day 4 post partum / Number of pups born alive) x 100

Results and discussion

Results: P0 (first parental generation)

Details on results (P0)

- Mortality: No mortality occurred during the study period that was considered to be related to treatment with the test substance. One female at 50 mg/kg bw/day died after blood sampling. In the absence of any adverse findings for this female, her accidental death was considered to have been caused by complications during the blood sampling procedure rather than to be related to treatment with the test substance.
- Clinical signs: No clinical signs of toxicity were noted during the observation period. Salivation was seen after dosing among animals of the 50 and 150 mg/kg bw/day dose groups (both sexes) from the end of treatment Week 2 onwards. This finding was considered to be a physiological response rather than a sign of systemic toxicity considering the nature and minor severity of the effect and its time of occurrence (i.e. after dosing). It may be related to irritancy/taste of the test substance. Incidental findings that were noted included alopecia and scabbing. These findings occurred within the range of background findings to be expected for rats of this age and strain which are housed and treated under the conditions in this study. At the incidence observed, these were considered signs of no toxicological relevance.
- Functional observations: Hearing ability, pupillary reflex, static righting reflex and grip strength were normal in all animals. Locomotor activity as determined by total movements and ambulations were comparable in all groups (both sexes). Mean values remained within the normal range of biological variation. All groups showed a comparable habituation profile with high activity in the first interval that decreased over the duration of the test period. For one control female (no. 45), mean values for total movements (2114) and ambulations (401) were relatively low, with mean values at the lower end of the normal range (total movements: P5 = 2006, ambulations: P5 = 408). No explanation could be given for this finding. All other functional observation parameters were normal and there were no supportive clinical signs (i.e. diminished general activity or abnormal gait).
- Body weights: No toxicologically relevant changes in body weights and body weight gain were noted. The statistically significant changes noted for body weight gain (on Day 1 of mating for females at 15 and 150 mg/kg bw/day and on Days 4 and/or 7 post-coitum for females at 50 and 150 mg/kg bw/day) were considered to be of no toxicological relevance as values remained within the range considered normal for rats of this age and strain and/or changes occurred in the absence of a treatment-related distribution.
- Food consumption: No toxicologically relevant changes in food consumption before or after allowance for body weight were noted. The statistically significant increase in absolute food consumption for females at 150 mg/kg bw/day on Days 4-7 post-coitum was considered to be of no toxicological relevance as it was only a very slight increase and remained within the range considered normal for rats of this age and strain.
- Haematology: No toxicologically relevant changes occurred in haematological parameters of treated rats. Minor statistically significant differences arising between controls and treated animals were considered not to represent a change of biological relevance. These findings included a higher haematrocrit value for males at 50 mg/kg bw/day, lower mean corpuscular haemoglobin concentration for males at 15, 50 and 150 mg/kg bw/day and higher white blood cell count for females at 150 mg/kg bw/day. Since changes were very slight, occurred in the absence of a dose-related trend, and/or values remained within the range considered normal for rats of this age and strain, they were considered of no toxicological relevance.
- Clinical biochemistry: Statistically significant differences arising between controls and treated animals were noted for females only. These changes included decreased levels of total protein at 150 mg/kg bw/day and decreased albumin at 150 mg/kg bw/day Other statistically significant changes in clinical biochemistry parameters of females were considered to be without toxicological relevance. Slightly lower albumin levels at 15 mg/kg bw/day occurred without dose dependency. The slightly higher level of aspartate aminotransferase (ASAT) at 15 mg/kg bw/day occurred in the absence of a dose-related trend. The lower glucose at 150 mg/kg bw/day was not considered to be treatment related because the difference was in part due to slightly high values obtained for controls and remained in the range considered normal for animals of this age and strain. For males, clinical biochemistry parameters were unaffected by treatment up to 150 mg/kg bw/day.
- Macroscopic examination: Macroscopic observations at necropsy did not reveal any alterations that were considered to have arisen as a result of treatment. The incidence of findings among control and treated animals was within the background range of findings that are encountered among rats of this age and strain, and did not show a dose-related incidence trend. These necropsy findings were therefore considered to be of no toxicological relevance. They included reddish discolouration or enlargement of the mandibular lymph node(s), alopecia, isolated, several or many tan, reddish or dark-red foci on the thymus, lungs, clitoral gland or glandular mucosa of the stomach, pelvic dilation of the kidneys (unilateral or bilateral), enlarged spleen, liver with the left lateral lobe reduced in size, uterus containing fluid or uterus with an enlarged right horn with black contents. The latter observation corresponds to the microscopy finding of cystic dilation and eosinophilic contents.
- Organ weights: Statistically significant higher liver weights (absolute and relative to body weight) were recorded for males, but not females, at 15, 50 and 150 mg/kg bw/day. There were no other effects on organ weights or organ to body weight ratios at any dose level tested.
- Microscopic examination: No toxicologically relevant changes were noted at the microscopic level. There appeared to be an increased severity of hemopoietic foci in the spleen of female rats treated at 150 mg/kg bw/day. After examination of the spleens of the selected 15 (Group 2) and 50 (Group 3) mg/kg bw/day treated female rats, no dose response relation was present and the severity grades scored in the 150 mg/kg bw/day treated rats were considered to be within normal limits for this study. There appeared to be a small increase in incidence of tubular basophilia in the kidneys of 2/5 female rats treated at 150 mg/kg bw/day. After examination of the kidneys of the selected 15 (Group 2) and 50 (Group 3) mg/kg bw/day treated female rats, no dose response relation was present. The incidences and severity grades scored (up to slight) in the 150 mg/kg bw/day treated rats were considered to be within normal limits and there were no concomitant kidney findings indicating a test item related effect. The assessment of the integrity of the spermatogenetic cycle did not provide any evidence of impaired spermatogenesis. There were no morphological findings in the reproductive organs of either sex which could be attributed to the test item. All remaining microscopic findings recorded were considered to be within the normal range of background pathology encountered in rats of this age and strain and in this type of study.
- Reproduction data: No toxicologically relevant effects on reproductive parameters were noted. Mating, fertility and conception indices, precoital time, and number of corpora lutea and implantation sites were unaffected by treatment. In the control group, three females did not mate in the first pairing period of 15 days. After cohabiting these females with a proven male, two females showed evidence of mating, though the third female (no. 48) did not. For this female implantation sites were noted in the uterus at necropsy indicating that she had been pregnant, but probably lost the conceptus during pregnancy. At 50 or 150 mg/kg bw/day, there were three and two non-pregnant females, respectively. Consequently, the number of litters available for evaluation of developmental data was 9, 10, 7 and 8 in the control, 15, 50 or 150 mg/kg bw/day groups, respectively.
- Developmental data: Gestation index and duration of gestation were not affected by treatment. No signs of difficult or prolonged parturition were noted among the pregnant females. For one female at 15 mg/kg bw/day (no. 53) bleeding from the vagina was noted on lactation Day 1. No toxicological relevance was attached to this isolated finding. Examination of cage debris of pregnant females revealed no signs of abortion or premature birth. No deficiencies in maternal care were observed.

Effect levels (P0)

1

Dose descriptor:

NOAEL

Remarks:

parental

Effect level:

150 mg/kg bw/day (actual dose received)

Based on:

test mat.

Sex:

male/female

Basis for effect level:

other: There were no findings that were considered to be adverse in nature following treatment up to 150 mg/kg bw/day.

2

Dose descriptor:

NOAEL

Remarks:

reproduction

Effect level:

150 mg/kg bw/day (actual dose received)

Based on:

test mat.

Sex:

male/female

Basis for effect level:

other: There were no findings that were considered to be adverse in nature following treatment up to 150 mg/kg bw/day.

Results: F1 generation

Details on results (F1)

Number of dead and living pups at first litter check, postnatal loss, viability index and sex ratio were unaffected by treatment, and clinical signs, body weight and external macroscopy did not reveal treatment-related findings. The number of pups found dead or went missing during the first days of lactation were 2, 1, 1 and 3 in the control, 15, 50 and 150 mg/kg bw/day groups. Pups that went missing were most likely cannibalised. No toxicological relevance was attributed to these dead/missing pups since the mortality incidence did not show a dose-related trend and remained within the range considered normal for pups of this age. There were no clinical signs that were considered a sign of toxicity. Incidental findings included a blue spot on the snout, scabbing on the abdomen, and pale or cold appearance. The nature and incidence of these clinical signs remained within the range considered normal for pups of this age, and were therefore considered to be of no toxicological relevance. Body weights of pups were comparable in all groups. Incidental macroscopic findings of pups that were found dead included no milk in the stomach, beginning or moderate autolysis, cannibalism (left inguinal region or all abdominal organs missing). For one surviving pup black discolouration of the tail apex was recorded. The nature and incidence of these findings remained within the range considered normal for pups of this age, and were therefore considered to be of no toxicological relevance.

Effect levels (F1)

Dose descriptor:

NOAEL

Remarks:

developmental

Generation:

F1

Effect level:

150 mg/kg bw/day (actual dose received)

Based on:

test mat.

Sex:

male/female

Basis for effect level:

other: There were no findings that were considered to be adverse in nature following treatment up to 150 mg/kg bw/day.

Overall reproductive toxicity

Reproductive effects observed:

not specified